AMPLY Discovery Receives Investment From Keeps Biomed

Why It Matters

The infusion of capital and scientific leadership positions AMPLY to fast‑track AI‑driven oncology programs, potentially reshaping drug discovery pipelines and offering investors exposure to next‑gen cancer therapeutics.

Key Takeaways

• Keeps Biomed invests in AMPLY Discovery, amount undisclosed.
• Funding targets oncology research and pipeline expansion.
• AMPLY uses evolution-powered AI on multi-omic data.
• New CSO Oliver Rausch joins to steer scientific strategy.
• Partnership aims co‑developing differentiated cancer therapies.

Pulse Analysis

The biotech sector is witnessing a surge in AI‑enabled drug discovery, and AMPLY Discovery sits at the forefront of this transformation. Originating from Queen’s University Belfast, AMPLY has built a platform that leverages evolution‑inspired algorithms to parse vast multi‑omic datasets, pinpointing disease‑relevant signals hidden in non‑coding regions of the genome. By securing strategic backing from Keeps Biomed, the company gains not only financial resources but also a gateway to the Asian market, where demand for innovative oncology solutions is rapidly growing.

AMPLY’s partnership with Keeps Biomed is more than a simple cash infusion; it creates a collaborative pipeline for co‑developing cancer therapeutics. The investment will fund pre‑clinical programs that translate computational hits into validated, partner‑ready assets, accelerating timelines that traditionally span years. The addition of Dr. Oliver Rausch, formerly of Storm Therapeutics, as chief scientific officer strengthens the scientific rigor of the portfolio, ensuring that AI‑derived candidates meet stringent efficacy and safety benchmarks before advancing to clinical stages.

For investors and industry observers, this deal signals a broader trend of cross‑border collaborations that blend deep learning expertise with biotech commercialization capabilities. South Korean firms like Keeps Biopharma are increasingly looking to European AI innovators to diversify their pipelines, while companies such as AMPLY gain access to capital and market channels that can propel their discoveries into global oncology trials. As AI continues to mature, partnerships that combine computational power with robust laboratory validation are likely to become the new standard for accelerating drug development and delivering differentiated therapies to patients.

AMPLY Discovery Receives Investment from Keeps Biomed

By FinSMEs · February 13, 2026 · Dermot Tierney (AMPLY, COO), Ben Thomas (AMPLY, CEO), Oliver Rausch (AMPLY, CSO)

AMPLY Discovery, a Belfast, Northern Ireland, UK‑based developer of an AI‑driven drug discovery platform, received a strategic investment from Keeps Biomed, a subsidiary of the South Korean biotechnology firm Keeps Biopharma.

The amount of the deal was not disclosed.

The company intends to use the funds to advance its oncology research, enhance its drug discovery pipeline, and explore new collaborative development opportunities in the cancer‑treatment space.

Led by CEO Dr. Ben Thomas and COO Dermot Tierney, AMPLY Discovery advances a platform that utilizes evolution‑powered AI to analyze multi‑omic datasets and identify disease signals within non‑coding genomic regions. The company, which originated as a spin‑out from Queen’s University Belfast, focuses on transforming computational findings into validated, partner‑ready therapeutic assets through rigorous laboratory testing.

The firm has established a portfolio model to address high unmet medical needs and has entered into a strategic partnership with Keeps Biopharma to co‑develop differentiated oncology programs.

In conjunction with the investment, AMPLY Discovery has appointed Dr. Oliver Rausch, formerly of Storm Therapeutics, as Chief Scientific Officer to oversee portfolio progression and technical strategy.

FinSMEs – 13/02/2026

Tags: AMPLY Discovery, Keeps Biomed